1
. Over the past five decades, the clinical presentation of PHPT has changed in several regions of the world 2 . Since the 1970s, PHPT has become more routinely diagnosed at an asympto matic stage owing to increased screening 2 . The clinical evolution of PHPT from symptomatic to asymptomatic has occurred primarily in the United States and Europe, although other countries have more recently appreciated this change as well 3 . One of the vexing issues that clin icians deal with is whether the asymptomatic patient has evidence of target organ involvement. This is the reason why this group of patients has been the subject of such intense interest over the past four decades.
Comparing prevalence and clinical aspects of the dis ease within and between countries is problematical owing to varying levels of screening availability and sources of information (for example, referral centres versus country demographics). Nevertheless, summarizing the varying presentations of PHPT globally is instructive.
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and skeletal manifestations has markedly decreased in the past 40 years. In addition, prevalence data show considerable sex and ethnic differences. The Kaiser Permanente Health Care database in California, USA, showed a significantly higher incidence of PHPT among black individuals (92 per 100,000 in women and 46 per 100,000 in men) than in white individuals (81 per 100,000 in women and 29 per 100,000 in men) 5 . Other races demonstrated a lower incidence. In Asian American populations, for example, the incidence was 52 per 100,000 in women and 28 per 100,000 in men.
In the Hispanic population, the incidence was 49 per 100,000 in women and 17 per 100,000 in men 5 . During the 15year period of this study, the Kaiser Permanente Health Care database showed an overall threefold increase in incidence, which is perhaps a reflection of increased screening 5 (FIG. 1) . Another survey con ducted in the United States estimated a PHPT prevalence of 0.86% for the general population 6 . The prevalence of normocalcaemic and hypercalcaemic PHPT in Canada was evaluated in the Canadian Multicenter Osteoporosis Study 7 and was found to be 3.3% and 1.4%, respectively. In the United States, a 60% increase in the incidence of parathyroid cancer, a very rare presentation of PHPT, was reported between 1988 and 2003 (REF. 8 ). This appar ent increase could be owing to greater awareness of the entity and uncertainty, at times, in the pathological characteristics of parathyroid cancer versus parathyroid adenoma and the tendency, over the years, to favour a cancer diagnosis when uncertain.
Europe
In Europe, PHPT is also identified most commonly as a relatively common, asymptomatic disorder. A Swedish study identified PHPT in 1.6% of women and 0.3% of men 9 . The incidence of PHPT also increased in Denmark between 1999 and 2010 (REF. 10 ), probably reflecting increased screening. Monitoring in Scotland, UK, over a 20year period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) showed, as has been shown everywhere, that PHPT predominantly affects women 11 .
Latin America
In Latin America, 47% of patients presented with asymp tomatic disease in a case series of 124 patients, whereas 25% had overt skeletal manifestations 12 . Approximately 44% of people with PHPT had kidney stones at the time of presentation in a study from Argentina 13 . In Brazil, 81.8% of patients were asymptomatic at the time of presen tation 14 . However, kidney stones and osteitis fibrosa cystica (a distinct PHPTassociated complication that is associated with bone loss, excessive fibrosis of the collagen matrix and the formation of bone cysts) were present in 18.2% and 6.1% of patients, respectively. The mean age was 61.1 years (±16 years).
Asia
Although epidemiological studies on the prevalence of PHPT have not been conducted in Asian countries, it seems that, in countries such as China and India, patients with PHPT still present with classic PHPT, namely, with organ manifestations and relatively high serum levels of calcium 15, 16 . However, a clear trend for PHPT to present more commonly as an asymptomatic disorder in China has been emerging over the past 5-10 years 17 . In the 35year period between 1958 and 1993, 97% of PHPT in China was characterized by kidney stones, classic skeletal lesions (for example, osteitis fibrosa cystica, generalized skeletal demineralization and pathological fractures) and other features of symptomatic PHPT 16 . Recently, the clinical profile of 249 patients with PHPT who were diagnosed and treated from 2000 to 2010 in one clinical centre in China was compared to American patients 17, 18 . Chinese patients were younger (51.3 years of age) than American patients (66.4 years of age) at diagnosis and were less likely to be women (female/male ratio of 2.07/1) than patients in New York City, USA (female/male ratio of 4.5/1). The average calcium levels (11.7 ± 1.4 mg per dl in China versus 10.6 ± 0.6 mg per dl in the United States), PTH levels (402 pg per ml (range: 103-2,700 pg per ml) in China versus 68 pg per ml (range: 48-95 pg per ml) for the United States) and creatinine levels (1.03 mg per dl (range: 0.55-2.75 mg per dl) for China and 0.79 mg per dl (range: 0.59-1.23 mg per dl) for the United States) in serum were all significantly higher, whereas the aver age 25hydroxyvitamin D concentration (13 ng per ml (range: 5-30 ng per ml) in China versus 37 ± 16 ng per ml in the United States) was much lower. Among all Chinese patients, 60% manifested classic symptoms related to PHPT, including polydipsia and polyuria (79.7%), kidney stones (78.4%), bone pain (69.9%) and fatigue (62.8%).
However, the clinical profile of Chinese patients is changing. The proportion of asymptomatic patients with PHPT rose from <20% before 2006 to ~50% in the period 2007-2010. This change has largely been driven by the availability of routine serum calcium testing and the incidental discovery of a parathyroid gland on neck ultrasonography 17 . A survey in Hong Kong, China, also demonstrated a steady increase in the prevalence of asymptomatic PHPT from 5% between 1973 and 1982 to 39% between 1983 and 1992 and to 59% between 1993 and 2002 (REF. 19 ).
Although China seems to be witnessing a change in the clinical presentation of PHPT, other Asian countries including India, Iran, Pakistan, Saudi Arabia and Thailand still mostly report symptomatic PHPT; asymptomatic PHPT remains rare in these regions (0-2.2% of all PHPT diagnoses) 15, [20] [21] [22] [23] [24] . The num  ber of patients diagnosed in a single centre in north  India steadily increased between 1990 and 2010, with  28 cases diagnosed during 1990-1999 and 174 cases  during 2000-2010. PHPT was predominantly diag nosed in women (70.3%), and virtually all 202 patients (99.1%) were symptomatic with kidney and skeletal involvement 25 . A similar presentation was described in Western India 20 . Parathyroid carcinoma has been reported in 6% of patients with PHPT in China (a total of 235 patients) and was even as high as 11.5% (a total of 87 patients) in Japan 17, 26 . These figures are much higher than in countries in the west. However, a decreasing trend for the incidence of parathyroid carcinoma over the past 10 years was noted in Chinese patients with PTHT 17 .
Africa and Australia
Information about PHPT in Africa is limited. A retro spective analysis of 28 patients with PHPT in a refer ral hospital in Durban, South Africa, between 2003 and 2009 reported that PHPT was still presenting with symptoms 27 . In a recent study from Australia, 561 patients with PHPT were followed up for >30 years. Mortality figures were higher than the general Australian population 28 .
Summary
In summary, the breakdown of individuals with symp tomatic versus asymptomatic PHPT has regional speci ficity. In countries for which screening biochemistries are not routinely part of the health care system, sympto matic PHPT seems to predominate. In countries where screening biochemistries are routine, asymptomatic PHPT takes centre stage. In short, symptomatic disease tends to be more common in countries where the preva lence is lower. All studies, independent of the breakdown of symptomatic versus asymptomatic PHPT in a given country, have shown that postmenopausal women are affected much more commonly than men. The incidence rates between premenopausal women and men are simi lar 5 . European studies suggest increased mortality 29 , but mortality rates are not higher in North America 30 .
Mechanisms/pathophysiology
The pathophysiology of PHPT relates to the loss of the homeostatic control of PTH synthesis and secretion (FIG. 2) , leading to increased PTH secretion by individual cells or increased parathyroid cell proliferation, but with each cell secreting a normal level of PTH.
In parathyroid hyperplasia, the increased number of parathyroid cells maintain their normal sensitivity to cal cium, whereas in parathyroid adenomas, the parathyroid cells show a lower than normal sensitivity to the inhib itory action of calcium (REFS 31, 32) . Both conditions give rise to PHPT and can cause hypercalcaemia.
PTH endocrine axis and target tissues
Calcium is the main regulator of PTH secretion, with an inverse sigmoidal relationship between calcium concentration and PTH release that is mediated by the interaction of calcium with the calciumsensing recep tor (CASR) present on the surface of parathyroid cells An increase in the serum levels of phosphate indirectly stimulates PTH synthesis and secretion as well as para thyroid cell proliferation by binding to calcium, thereby lowering the serum calcium concentration 35 . Some stud ies have suggested that serum phosphate can directly affect para thyroid cell function by increasing PTH mRNA stability 36 . Finally, studies in rats and rat para thyroid cell cultures have shown that fibroblast growth factor 23 (FGF23), released from osteocytes (bone cells involved in mechanosensing and mineral homeostasis), inhibits PTH synthesis and secretion and, perhaps, para thyroid cell proliferation by binding to its cognate FGF receptor 1 (FGFR1) and the coreceptor Klotho on the membrane of parathyroid cells 37 . The relevance of this observation to the pathogenesis of PHPT in humans remains uncertain. Indeed, patients with PHPT have increased levels of FGF23 in association with high serum levels of PTH, suggesting that the increased FGF23 levels might be an adaptive response to counteract increased 1,25(OH) 2 D levels as a consequence of high PTH levels 38 .
The main target organs of PTH are the bone and the kidney. PTH is a central regulator of bone homeostasis, through its action on boneforming osteoblasts, osteo cytes and boneresorbing osteoclasts 39 . The final effect of PTH on bone mass is either anabolic or catabolic and will depend on the dose and periodicity of PTH signal ling 40 . In healthy individuals, PTH is released both with circadian dynamics and in a pulsatile manner, such that its dual anabolic and catabolic actions are well balanced. Conversely, in patients with PHPT, the chronically increased PTH levels lead to bone loss mediated by the receptor activator of nuclear factorκβ ligand (RANKL, also known as TNFSF11), osteoporosis (particularly at sites that are more rich in cortical bone) and fragility fractures. It is not clear to what extent changes in these secretory dynamics are associated with bone loss and fragility fractures in PHPT 41 . In the kidney, PTH stimulates tubular calcium reabsorp tion and phosphate excretion and stimulates the activity of 1α25hydroxyvitamin D hydroxylase. When patients with PHPT develop hypercalciuria, the filtered calcium load is greater than the capacity of the kidney to reabsorb calcium efficiently, even under the influence of PTH 42 .
Aetiological factors of tumorigenesis
PHPT is usually (>90%) sporadic and caused by a solitary benign adenoma (85-90%), less frequently by multi glandular involvement consisting of either multiple adenomas or hyperplasia of all four glands (5-10%), and very rarely by parathyroid carcinoma (<1%) 43 . Multiglandular involvement may present in an asynchronous manner and, therefore, can be confused with singlegland adenoma when only one abnormal gland is found at the time of initial surgery 44 . Over time, another parathyroid adenoma can become clinically evident. Conversely, multiple adenomas, present ing simultaneously, can also occur 45 . Very rarely, PHPT may be caused by ectopic secretion of PTH by a nonparathyroid tumour 44 . The aetiology of PHPT remains elusive in the majority of patients. A history of external neck irradi ation in childhood 46 , exposure to a nuclear incident in adults 47 and longterm lithium therapy (as opposed to shortterm lithium therapy that may cause second ary hyper parathyroidism) 48 are present in a few cases. PHPT may also be part of hereditary endocrine syn dromes, including multiple endocrine neoplasia type 1 (MEN1) and MEN2A, MEN4 (which is a MEN1like condition (associ ated with one or more of the main MEN1associated tumours, but without MEN1 gene mutations), hereditary hyperparathyroidismjaw tumour syndrome, familial isolated hyperparathyroidism, famil ial hypocalciuric hypercalcaemia (FHH) and neonatal severe hyperpara thyroidism (TABLE 1) . The identifica tion of hereditary cases can sometimes be difficult in the absence of a family history and, in these settings, a de novo germline mutation should be considered.
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Molecular mechanisms of tumorigenesis
Evaluation of the clonal status of a parathyroid tumour (including adenomas and carcinomas), has shown that most are monoclonal, which implies that the tumours derive from a single abnormal cell 49, 50 . By contrast, hyperplastic parathyroid glands probably originate from a stimulus for generalized (polyclonal) parathyroid cell proliferation, even though monoclonal tumours may also occur in this context 51 . Thus, in some cases, apparently hyperplastic glands are in fact adenomas. The clonality of parathyroid tumours has also been shown in MEN1 (REFS 52, 53) .
The clonality of most parathyroid tumours suggests the involvement of genes that control parathyroid cell growth and/or PTH synthesis or secretion. Two broad categories of genes might be involved: protooncogenes and tumoursuppressor genes (FIG. 4) . Notably, tumori genesis is often a multistep process during which cells acquire a series of mutations or deletions in multiple genes, which can in some instances coexist. Moreover, epigenetic changes could contribute, in certain speci fic ways, to tumour development. Several genes have been implicated in sporadic and hereditary forms of PHPT. Although syndromic forms account for <10% of PHPT, the identification of genes involved in the pathogenesis of inherited forms has contributed to the understanding of parathyroid tumorigenesis. FIGURE 5 summarizes the main molecular mechanisms involved in parathyroid tumorigenesis. More than 1,000 muta tions have been identified in ~80% of probands and fam ilies with MEN1. The mutations are distributed across the translated region of the gene without hotspots; the major ity of mutations predict truncation or the absence of the encoded protein (menin) 55 . Individuals with MEN1 typic ally inherit the inactivating germline mutation from an affected parent, but up to 10% of affected individuals have a de novo germline mutation. An acquired somatic inactiv ation of the other copy of MEN1 in one para thyroid cell, leading to the absence of functional menin, contributes to the clonal origin of the parathyroid tumour and other tumours in the patient 54 
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(FIG. 5).
Menin is a 610 amino acid protein that interacts in vitro with various proteins, including the transcrip tion factor AP1 (encoded by JUN), nuclear factorκB and the SMAD transcription factors, as well as other cell cycle regu lators and cytoskeletal proteins, all suggesting a role in multiple biological pathways 56 . The interaction of menin with a histone methyltransferase complex, including the histonelysine Nmethyltransferases MLL1 (encoded by KMT2A) and MLL2 (encoded by KMT2D), can be involved in MEN1associated tissueselective tumori genesis 57 , mediated by the transcriptional acti vation of CDKN1B (encoding cyclindependent kinase inhibitor 1B) and CDKN2C 58, 59 . Recently, a germline mutation of the aryl hydrocarbon receptor interacting protein gene (AIP) has been reported in a patient with sporadic MEN1 syndrome 60 . Mutations of other genes, encoding cyclindependent kinase inhibitors, including CDKN1A, CDKN1B (MEN4, see below), CDKN2B and CDKN2C, have been identified in MEN1 mutationnegative kindreds with MEN1 disease 61 .
Multiple endocrine neoplasia type 2A. The inheritance of MEN2A is autosomal dominant and due to gainof function mutations in the RET protooncogene (TABLE 1) . RET is a tyrosine kinase receptor that is involved in the control of growth and differentiation in developing tissues, including those derived from the neural crest. A RET mutation at codon 634 is highly associated with the development of PHPT Figure 3 | Relationship between calcium and parathyroid hormone levels in normal conditions and in PHPT. In normal conditions, the level of parathyroid hormone (PTH) secretion depends on the level of calcium, with a high level of PTH secreted when serum calcium is at the lower limit of the normal range and a low level when serum calcium is at the upper limit of the normal range. The range of normal serum calcium levels is indicated by the shaded area. The calcium set point corresponds to the concentration of calcium, which reduces PTH secretion by 50%. In primary hyperparathyroidism (PHPT), the parathyroid adenoma is relatively insensitive to the feedback suppression by calcium, and the curve is shifted to the right with an increase in the set point for serum calcium. As a consequence, PHPT is often associated with hypercalcaemia. in 10-25% of patients with MEN2A; in ~50% of patients that develop tumours, no hypercalcaemia is observed 62 .
Multiple endocrine neoplasia type 4. In 2006, Pellegata et al. 63 described a rat model that spontaneously developed multiple neuroendocrine tumours, with a spectrum similar to that of MEN1 and MEN2 syndromes. The same authors showed that a homozygous germline mutation in Cdkn1b, encoding p27, was responsible for this condition, which was named MENX 63 . Heterozygous germline mutations of the human homologue CDKN1B were identified in kindreds with classic MEN1associated tumours (for example, pituitary, parathyroid and pancre atic tumours) occurring in association with uncommon MEN1associated or nonassociated tumours (for exam ple, adrenal and thyroid tumours, and gonadal and renal tumours, respectively) without a mutation in MEN1 (REF. 64 ). These kindreds with MEN1associated tumours and CDKN1B mutations are now designated as a new syndrome called MEN4 (REFS 65, 66) (TABLE 1) . In G1 phase cells (resting), p27 (KIP1) is found in the nucleus, where it controls cell cycle progression from G1 to S phase, the mechanism for which involves inhibiting the cyclin E-CDK2 and cyclin A-CDK2 complexes. In proliferating cells, p27 (KIP1) is also localized to the cytoplasm, where it seems to have a prooncogenic function 67 .
Hereditary hyperparathyroidism-jaw tumour syndrome. Mutations in CDC73 are responsible for hereditary hyperparathyroidismjaw tumour syn drome 68, 69 (TABLE 1) . This is a rare autosomal disorder consisting of parathyroid tumours, with a high preva lence of parathyroid carcinomas (15%), ossifying fibro mas of the mandible and maxilla and, occasionally, renal and uterine lesions. CDC73 is a tumoursuppressor gene that encodes parafibromin, a 531 amino acid nuclear pro tein that is also expressed in the kidney, heart, adrenal glands and skeletal muscle. Parafibromin is a member of the human polymeraseassociated factor 1 (PAF1) complex, which regulates transcription and chromatin modification 70 (FIG. 5) . 33 . Gene inactivation studies in mice support the pathogenetic role of CASR inactivation in FHH type 1 and neonatal severe hyperparathyroidism 76 . Sporadic form of PHPT Parathyroid adenoma. Overexpression of cyclin D1 (encoded by CCND1) and mutations of MEN1 are wellknown factors in the pathogenesis of sporadic para thyroid adenomas 44 . CCND1 was discovered in parathyroid adenomas and mapped on 11q13. In these tumours, a pericentromeric inversion causes a tumourspecific DNA rearrangement of CCND1 with PTH and is responsible for transcriptional activation and overexpression of cyclin D1 (REFS 77, 78) (FIG. 5) . This genetic abnormality has been detected in ~8% of sporadic parathyroid adenomas, although an increased expression of CCND1 has been reported in ~20-40% of cases. Cyclin D1 plays an important part in the regula tion of cell cycle progression. Its effects on proliferation are mediated by the phosphorylation of retinoblastoma protein (RB). Biallelicacquired inactivating MEN1 mutations have been described in 12-35% of sporadic parathyroid adenomas [79] [80] [81] . Other genetic abnormalities have been detected in a small proportion of parathyroid adenomas, including mutations in CDC73 (REFS 82, 83) , CDKN1B 84 and AIP
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. Interestingly, mutations were germline in two patients with CDKN1B mutations and in one carrying a mutation in AIP. Contradictory results have been reported on the presence of CTNNB1 (encoding βcatenin) mutations involving serine/threonine phosphorylation 86, 87 . Up to 30 proteins, involved in various cellular pathways (for example, response to biotic stimuli, cell organization and signal transduction), are differentially expressed in nor mal parathyroid and parathyroid adenomas 88 . Of these various proteins, 1433ζ/δ may be one of the key proteins in the pathogenesis of parathyroid adenoma.
Parathyroid carcinoma. Loss of RB1 expression in para thyroid carcinoma was initially reported by Cryns et al. 89 and was proposed as a diagnostic tool, but contradic tory results were shown by others 90 and no abnormali ties in the coding or promoter regions of RB1 have been identified 91 . CDC73 is the most common mutated gene (up to 70%) in sporadic parathyroid carcinoma 69, 90, 91 . Interestingly, mutations are germline in about one third of patients, suggesting that they may be affected by hereditary hyperparathyroidismjaw tumour syndrome or a variant instead of sporadic tumours 90, 91 . Another mechanism of CDC73 inactivation -methylation of the promoter -has been reported in a small subset of parathyroid carcinoma 92 . Recently, using wholeexome sequencing, germline and somatic mutations have been detected in 4 out of 22 (18%) patients with parathyroid carcinoma. Occasional mutations of MEN1 have also been reported 93 . Two recent studies suggest a potential role of microRNA296 as a novel oncosuppressor gene in parathyroid carcinoma 94, 95 . 
Diagnosis, screening and prevention
Clinical manifestations
Osteitis fibrosa cystica describes the skeletal manifesta tions of PHPT when the disease is advanced. It is typi cally characterized by bone pain, skeletal deformities and pathological fractures 12 (FIG. 6) . Conversely, in asympto matic PHPT, skeletal involvement is typically seen only by bone mineral density (BMD) testing, which shows a reduction, especially of the cortical bone compartment best seen at the distal onethird of the radius site. Recent data using highresolution peripheral quantitative CT (HRpQCT) have demonstrated that both cortical and trabecular bone compartments are affected in PHPT 96, 97 . Involvement of the trabecular compartment is further documented by the trabecular bone score, which is also reduced in the lumbar spine 98, 99 , and by fractures that are increased at both vertebral and nonvertebral sites 100, 101 . These observations support recommendations to include vertebral imaging either by radiography, CT or verte bral fracture assessment to evaluate skeletal manifest ations of PHPT D1 (encoded by CCND1) , a regulatory subunit of cyclin-dependent kinase 4 (CDK4) and CDK6 required for progression through the G1 phase of the cell cycle, is frequently (20-40%) overexpressed in parathyroid adenomas. In a subset of these adenomas, a pericentromeric inversion of chromosome 11 places the parathyroid hormone gene (PTH) promoter sequences on 11p15 immediately upstream of CCND1. This rearrangement results in the upregulated expression of cyclin D1 upon activation of CDKs. (2) Loss-of-function mutations of MEN1 (which encodes menin) represent the main cause of multiple endocrine neoplasia type 1 (MEN1) syndrome (in up to 80% of cases), especially in the familial setting, but are also found in a subset of familial isolated hyperparathyroidism (FIHP) and in 12-35% of sporadic parathyroid adenomas. MEN1 functions as a classic tumour-suppressor gene and is frequently associated with somatic loss of heterozygosity. Menin is a component of the histone methyltransferase complex, including the histone-lysine N-methyltransferases MLL1 (encoded by KMT2A) and MLL2 (encoded by KMT2D), required for histone H3 lysine 4 trimethylation (H3K4Me) of the target genes. In physiological conditions, activation of this complex leads to the basal transcription of CDKN1B, encoding the CDK inhibitor p27 (KIP1), which stops progression of the cell cycle by inhibiting CDK complexes acting at multiple phases of the cell cycle, especially at G1-S and S-G2 checkpoints. MEN1 inactivation results in a reduction of nuclear expression levels of p27 (KIP1) and the loss of negative control of cell cycle progression. (3) CDKN1B germline mutations are the molecular cause of the MEN4 syndrome. CDKN1B is an atypical tumour-suppressor gene because biallelic inactivation is an uncommon event, suggesting that only a single inactivated copy of the gene is sufficient to lead to a diseased state (haploinsufficiency). (4) Somatic and germline inactivating CDC73 (which encodes parafibromin) mutations have been frequently identified in patients with parathyroid carcinoma. Germline CDC73 mutations are also responsible for hyperparathyroidism-jaw tumour syndrome (HPT-JT). Parafibromin binds to DNA and leads to repression of cyclin D1 and inhibition of proliferation. In case of CDC73 inactivation, parafibromin seems to associate with β-catenin, a central mediator of WNT signalling, and activates target genes (for example, MYC and CCDN1) through H3K4Me.
is associated with osteitis fibrosa cystica, the improve ment in BMD can be so marked as to increase into the normal range 42, 102 . The prevalence of kidney stones in PHPT has varied over the years and, to a certain extent, is dependent on the use of imaging modalities to detect them. Overt kidney stone disease (symptomatic kidney stones) has declined from 60% when series of PHPT were first reported about 50 years ago to morecurrent estimates of ~20% [103] [104] [105] . By contrast, abdominal imaging of asymptomatic patients with PHPT is yielding a higher prevalence of silent stones and nephrocalcinosis than was thought to be the case in asymptomatic PHPT 106, 107 . Weakness and fatigue were initially thought to be associ ated with a neuromuscular syndrome, character ized by atrophy of type II muscle fibres of the proximal musculature 108 . However, over time, as the disease has evolved into a more asymptomatic phenotype, these objective findings on neurological examination are no longer seen 109 . Among asymptomatic patients with PHPT, a detailed examination using electroneurography is required to disclose subtle abnomalities of peripheral nerves 110 . General symptoms -in particular, fatigue, weakness, anxiety and mood alterations -along with impairment in quality of life (QOL) may or may not improve after surgical cure (see below) 111 . Peptic ulcer disease, which used to be considered a frequent complication of PHPT, is now rarely seen and is almost exclusively detected in patients with MEN1 or MEN4 syndromes, who can develop gastrin producing tumours 112 . Similarly, the association between PHPT and acute pancreatitis, apart from that related to hypercalcaemia per se, remains to be established 113 . With regard to cardiovascular health, hypertension, premature atherosclerosis, valve calcification, left ven tricular hypertrophy and arrhythmias have been reported in patients with PHPT [114] [115] [116] , but the data on outcome as well as the mechanisms involved are inconclusive. The Nurses' Health study 114 showed an increased incidence of PHPT in women with hypertension compared with those with normal blood pressure values. In addition, no evi dence of increased left ventricular mass or diastolic dys function in patients with biochemically mild PHPT was found, but the finding of higher serum calcium and PTH levels in patients with diastolic dysfunction suggests that disease severity of PHPT may be associated with cardiac manifestations 115 . Iwata et al. 116 observed that mild PHPT was associated with subclinical aortic valve calcification. Serum PTH levels, but not serum calcium levels, were a more important predictor of aortic valve calcification than traditional cardiovascular risk factors.
Laboratory diagnosis
Confirmed hypercalcaemia is a major indicator of PHPT 117
. Either total calcium (albumin corrected) or ionized calcium can be measured. As ~45% of total serum calcium is bound to albumin, calculating the corrected calcium level involves adjusting the level of total serum calcium by the level of serum albumin. The many tech nical issues related to the direct measurement of ionized calcium lead many experts to recommend the adjusted total calcium as the best way to report the serum calcium concentration. It is helpful to repeat the serum calcium measure ments several times over the course of a 3-6month period and to retrieve histor ical serum calcium values that are available from the patient's record.
A major diagnostic linchpin in PHPT is the measure ment of circulating PTH. Secondgeneration assays that measure the socalled intact PTH molecule [PTH ] show crossreactivity with the large, inactive, amino truncated fragment [PTH ]. This fragment can also be detected in individuals without PHPT and can accu mulate in patients with renal failure. The thirdgeneration or biointact assay uses a labelled antibody that recognizes an extreme Nterminal PTH fragment [PTH(1-4)], pre venting crossreactivity with PTH(7-84). However, this assay also detects a posttranslational form of PTH in the region 5-20 that is not truncated. This posttranslationally modified form of PTH (NPTH) represents 10% of PTH in healthy individuals and 15% in patients with chronic kidney disease, and is not thought to be active. In para thyroid cancer, it seems to be overrepresented 118 . There are few studies comparing the diagnostic sensitivity between the secondgeneration and thirdgeneration assays, but both perform generally well 119 . In PHPT, the serum PTH levels may be frankly increased or in the normal range. However, a 'normal' PTH value in someone with hypercalcaemia is clearly not a normal physiological value. For example, in a large epidemiological study in Scotland, UK 11 , patients with hypercalcaemia on two or more occasions and an intact serum PTH concentration of >28 pg per ml (reference range: 19-65 pg per ml) were considered to have PHPT. Indeed, in individuals without PHPT who become hyper calcaemic, PTH should be completely suppressed and undetectable by immunoassay.
Normocalcaemic PHPT
Normocalcaemic PHPT has been increasingly detected in patients who are evaluated for low BMD 117 . Other causes of hyperparathyroidism due to a normal physio logical stimulus to increased PTH levels -secondary hyperparathyroidism states -should be excluded denosumab, usually cause increases in serum PTH con centrations, rendering a diagnosis of normo calcaemic PHPT under these conditions uncertain 120, 121 . The diag nosis of parathyroid gland autonomy in the setting of chronic kidney disease is more challenging. In patients with advanced chronic kidney disease, the presence of hypercalcaemia along with a progressive rise in serum PTH levels is usually referred to as tertiary hyperpara thyroidism. In advancedstage chronic kidney dis ease, intact PTH levels in serum should be maintained between 150 and 550 pg per ml to avoid lowturnover or highturnover bone disease 122 .
Evaluation of patients with PHPT
Laboratory evaluation should include measurements of serum phosphate, renal function tests and measure ments of serum 25hydroxyvitamin D
. The 24hour urinary calcium level should also be measured and, if >400 mg per day, a complete stone risk profile analysis should also be measured. A urinary calcium clearance/creatinine clearance ratio of <0.01 suggests, but does not prove, FHH; the age of the patient should also be taken into account as FHH exhibits virtually 100% penetrance by 30 years of age. In addition, in FHH, a family history of hypercalcaemia can often be obtained and should be followed by genetic screening.
Serum phosphate levels are usually low in severe PHPT and in the lower range of normal in milder forms of PHPT 123 . Bone turnover markers may be increased, the degree to which can be a function of the severity of the bone disease
. Renal imaging by ultrasound, Xray or CT should be performed to detect the pres ence of kidney stones or nephrocalcinosis. Measurement of BMD by dualenergy Xray absorptiometry should be obtained at the lumbar spine, the hip (total hip and femoral neck) and the distal onethird of the radius in all patients with PHPT. Depending on availability, additional tests such as the trabecular bone score or HRpQCT may be helpful 121 . In young patients with PHPT (<30 years of age), those with multiglandular disease, a family history of PHPT (affected firstdegree relatives) or in those with parathyroid cancer, specific genetic testing (TABLE 1) may be necessary 117 .
Management
Resection of a parathyroid adenoma (parathyroid ectomy) in patients with PHPT is usually curative 124, 125 . Following successful parathyroidectomy, biochemi cal abnormalities resolve and BMD improves 126 with a decreased risk of bone fracture 127 and kidney stones 128 . There may also be improvements in neurocognition and QOL, although randomized controlled trials (RCTs) have failed to show consistent effects [129] [130] [131] . Similarly, cardiovascular end points have not been consistently reached, which might be related to subtle preoperative cardiovascular abnormalities of which the physiological importance is not yet understood. Furthermore, short term outcome measures raise questions about longterm improvement and whether the initial abnormalities were clearly related to the disorder 132 . Patients with sympto matic disease should be referred for parathy roidectomy if there are no medical contraindications. Medical ther apy is an option for patients who meet surgical criteria but who cannot undergo surgery. The Conference Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism 121 provide guidance about which patients with asymptomatic disease should be referred for surgery or those who can be managed expectantly.
Surgical management
A focused approach to remove the single parathyroid adenoma is now the procedure of choice at experi enced surgical centres, with use of rapid intraoperative PTH measurements 133 . This procedure is preceded by successful localization of the parathyroid adenoma. Minimally invasive parathyroidectomy is not gener ally recommended unless the adenoma is identified by an imaging modality preoperatively. An example of a successful preoperative localization of a parathyroid adenoma is shown in FIG. 7 . The minimally invasive parathyroidectomy can be performed under local or regional anaesthesia with sameday discharge. Surgical cure rates with minimally invasive techniques in experi enced surgical centres exceed 98% with relatively low risk of surgical complications 124, 125 . Surgery should be considered for any patient who presents with evidence of symptomatic disease, includ ing kidney stones within 10 years of diagnosis or the presence of a fragility fracture. Surgery is also acceptable for asymptomatic patients, provided they do not have medical contraindications 121, 133 . The most recent revision 
. The revised guide lines take into account the increased risk of vertebral fracture risk and subclinical kidney stones in asympto matic individuals with PHPT 100, 101, 107 . Thus, the new guidelines recommend an evaluation for morphometric vertebral fractures and recommend further evaluation for nephrolithiasis or nephrocalcinosis, or increased risk of kidney stones (biochemical stone risk analysis).
The guidelines recommend genetic testing of patients suspected of having a genetic disorder, such as young patients (<30 years of age), patients with syn dromic findings and/or a positive family history of syndromic PHPT, and patients with multiglandular dis ease, parathyroid carcinoma or atypical adenoma 117, 121 . An atypical adenoma is defined histologically as con taining features that are not typical of a benign adenoma. Some of these atypical features include an abundance of mitotic figures and cellular atypia. Sometimes, the atypical adenoma will present at the time of surgery as oddly adherent to surrounding structures. The surgical approach for patients with a genetic aetiology may dif fer from those with a sporadic parathyroid adenoma, in that multi glandular disease is more common when there is a genetic aetiology. Preoperative localization studies are recommended with ultrasound, 99mtechnetium sestamibi nuclear scintigraphy, CT, MRI or PET scans. The choice of preoperative imaging depends on the experience of the surgical centre 133 .
Non-surgical management
Natural history and monitoring. Patients who do not meet surgical criteria or those who decline surgery should be monitored for signs of disease progres sion. The longest natural history study prospectively observed patients with primary hyperparathyroidism for 15 years 126 . Biochemical parameters remained stable for 12 years, with a trend towards increasing levels of serum calcium in years 13-15. BMD remained stable for the first 8-10 years of observation, with subsequent decline in densitometric parameters at the distal radius and hip. Over the 15year followup period, 37% of patients with asymptomatic PHPT ultimately developed one or more criteria for surgery.
The revised guidelines 121 recommend annual measure ments of serum calcium, serum creatinine and estimated glomerular filtration rate. BMD should be monitored every 1-2 years at the spine, hip and fore arm. Followup vertebral imaging with Xray or vertebral fracture analysis should be performed if clinically indi cated for a patient with prospective height loss or new back pain. Imaging for new kidney stones should be per formed if clinical suspicions emerge. Patients who do not meet criteria for parathyroidectomy on initial evaluation should be considered for surgical management if during the monitoring period serum calcium concentrations rise to >1 mg per dl above the upper normal limit, creatinine clearance falls to <60 cc per minute, the Tscore at the spine, hip or distal onethird of the radius site falls below -2.5 or there is a substantial reduction in BMD, or if a vertebral fracture or kidney stone develops 121 .
Medical management. Adequate hydration and avoid ance of dehydration is always recommended. Calcium intake should not be restricted and should follow national guidelines 135 . 25hydroxyvitamin D levels of >20 ng per ml are recommended, although some experts continue to recommend levels of >30 ng per ml. To replete vitamin D when needed, initial doses of 600-1,000 IU daily are recommended, although a recent study showed that doses of 2,800 IU daily were well toler ated 136 . Serum calcium levels should be monitored during vitamin D supplementation.
Cinacalcet, a calcimimetic, is approved for specific indications in PHPT by the European Medicines Agency (EMA) and the US FDA. The EMA approved the use of cinacalcet for patients with hypercalcaemia who meet surgical criteria but in whom parathyroidectomy is not possible or not clinically 'appropriate' (REF. 137 ). Concurrent medical contraindications to surgery would be an example. Another example is a patient with PHPT who has had several negative operations in search for the elusive adenoma. The FDA approval is for severe hypercalcaemia in patients with PHPT who are unable to undergo parathyroidectomy 138 . Adverse effects of cinacalcet include nausea, vomiting, diarrhoea and headache, but are uncommon when the single 30 mg daily dose is used. Approval of cinacalcet followed the pivotal randomized, doubleblind, placebocontrolled trial in PHPT 139 . The primary end point -normal ization of serum calcium levels -was achieved in 73% of enrolled patients. Serum calcium levels remained in the normal range during the 4.5year openlabel exten sion 140 . Subsequent prospective trials have shown similar results [141] [142] [143] . No significant effects on BMD have been observed with cinacalcet therapy.
Alendronate, a bisphosphonate, improved BMD in patients with PHPT 144, 145 . In a 2year randomized cross over study of alendronate versus placebo in postmeno pausal women, the alendronate group had a significant increase in lumbar spine BMD at 2 years compared with baseline and compared with the control group 144 . The total hip BMD increased at 1 year and subsequently remained stable. Serum and urine concentrations of cal cium and PTH did not change. A trial in men showed similar results 145 . Limited data suggest that oestrogen may also reduce bone resorption in PHPT, with no change in calcium or PTH levels 146 . In patients who require both a reduction in serum calcium levels and an improvement in BMD, combination therapy with cina calcet and alendronate is reasonable, but has only been studied in a retrospective manner 142, 147, 148 .
Normocalcaemic PHPT. The optimal management strategy for the normocalcaemic variant of PHPT has not been established, but the 2014 guidelines offer recom mendations 121 . Patients should be referred for para thyroidectomy if they have or develop complications of PHPT, even if they remain normocalcaemic. Serum calcium, PTH and creatinine levels should be monitored annually and BMD should be evaluated every 1-2 years.
Patients who develop hypercalcaemia can be managed as per the guidelines for asymptomatic PHPT. In one study, BMD improved following parathyroidectomy 149 in patients with hypercalcaemic PHPT 126, 150 . There are little data available about the impact of medical therapy on patients with normocalcaemic disease. Alendronate improved BMD in a small cohort 151 .
Quality of life
Although we define asymptomatic PHPT as a condition in which classic target organs are not affected, many such patients report nonspecific symptoms, including fatigue, irritability, weakness, malaise, somatization, lack of mental clarity, sleep disturbance, anxiety and depres sion. These nonclassic features of PHPT have been vex ing and inconclusive to date as far as their association with PHPT and their reversibility after successful para thyroidectomy are concerned. However, these relatively common complaints among many patients with PHPT recall the classic descriptions of the disease of "mental fuzziness" that resolved with parathyroidectomy 1 . Various crosssectional and prospective studies have shown conflicting results with regard to the non classic symptoms of PHPT and improvement follow ing parathyroidectomy [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] . The inconsistency of the data among these studies did not permit the expert Workshop Panel of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism to recommend parathyroid sur gery if such symptomatology was present in the absence of any clear surgical guidelines 121, 134 . Walker and colleagues 163 published one of the most detailed neuropsychiatric evaluations in individuals with PHPT (TABLE 2) . Thirtynine postmenopausal women with mild, asymptomatic disease were prospec tively studied before and after parathyroidectomy com pared to 89 healthy agematched controls. A battery of validated instruments to measure cognition and their relation ships to underlying psychological symptoms and biochemical disease severity were used. At baseline, individuals with PHPT had worse symptom scores for depression and anxiety and worse performance on tests of verbal memory and nonverbal abstraction than con trols. Six months following parathyroidectomy, these • Age <50 years • Serum calcium concentration of ≥1 mg per dl above the upper normal limit • T-score at or below -2.5 at the lumbar spine, femoral neck, total hip or distal one-third of the radius, or the presence of vertebral fracture by X-ray or vertebral fracture assessment • Creatinine clearance of <60 ml per minute, increased risk of kidney stones by biochemical stone risk analysis, and kidney stones or nephrocalcinosis by abdominal imaging variables improved and were no longer different than controls. Baseline differences in cognition and improve ment following parathyroidectomy were not associated with psychological symptoms or serum calcium or PTH concentrations. Various older, observational studies have demon strated deficits in QOL and neuropsychiatric features in individuals with the mild form of PHPT, with conflict ing data regarding symptomatic improvement follow ing parathyroidectomy. Many of these studies are unfortu nately limited by methodological flaws, including a fail ure to apply standardized evaluation tools, small sample sizes, lack of controls or an inappropriate control popu lation, and inclusion of subjects with symptomatic dis ease. A major problem inherent to this research is the lack of adoption of a validated diseasespecific tool to evaluate QOL. Most studies use the 36Item ShortForm Health Survey (SF36), one of the most widely used gen eral measures of QOL composed of eight domains on physical and mental health. Pasieka and colleagues 164 validated a diseasespecific QOL questionnaire, and Webb and colleagues 165 state that validation studies are in progress for their diseasespecific questionnaire.
The most rigorous data available are from RCTs of parathyroidectomy versus observation [129] [130] [131] . Rao et al. randomized 53 individuals with PHPT to observation versus parathyroidectomy and were followed up for up to 2 years. Five domains of the SF36 (social functioning, physical functioning, emotional role functioning, vitality and general health perception) significantly worsened during the 2year followup without surgery. Following parathyroidectomy, only modest, but significant, bene fits in social functioning and emotional role function ing were observed, with a significant decline in physical functioning. Using the Symptom CheckList90Revised scale (SCL90R), individuals in the surgical group demonstrated less anxiety and phobia than individ uals who were followed without surgery. No signifi cant differences were noted in the other domains and no significant worsening was noted in the individuals who were followed without surgery. Ambrogini et al. 130 randomized 50 individuals with PHPT who were fol lowed for up to 1 year. At 12 months, the surgical group had significantly improved scores for bodily pain, gen eral health perception, vitality and mental health com pared with medically managed controls, although the absolute differences were modest. No differences were noted in the remaining SF36 or SCL90R domains. Bollerslev et al. 131 randomized 191 subjects with PHPT who were followed for up to 2 years. They used the SF36 questionnaire and the modified Comprehensive Psychopathological Rating Scale (CPRS), using norma tive Swedish data as a comparison. At baseline, individ uals with PHPT had lower SF36 scores for vitality, social functioning, emotional role functioning, mental health and the mental health component summary than nor mative controls, as well as a lower CPRS score. A small but significant decrease in physical functioning and the physical component summary score was observed over 2 years in the observation group, whereas there were no changes noted in the surgical group. For the mental health domains, the surgical group had signifi cantly increased values for emotional role functioning and mental health at 1 year compared with baseline, but not at 2 years. At 2 years, the observation group had increased values for mental health from baseline. Using the CPRS questionnaire, both the observation and the surgical groups had significantly more symptoms than controls over the 2 years without significant change over time. There was a trend towards a better outcome in the surgical group at 1 year (P = 0.08) but not at 2 years.
Perrier et al. 166 randomized 18 subjects with PHPT to parathyroidectomy or observation and followed sub jects for up to 6 months in a pilot study of cognition in addition to sleep and brain function using functional MRI. No betweengroup differences in cognition, day time sleepiness or voxel counts by functional MRI were found at 6 months. Total sleep time and left precentral gyrus activity were found to be inversely correlated with PTH levels. 
Randomized controlled trials
Rao et al. 129 Modest but significant improvements in social functioning and emotional role functioning in individuals 1 year after parathyroidectomy compared with medical management (SF-36)
Modest but significant improvements in anxiety and phobia in individuals 1 year after parathyroidectomy compared with medical management (SCL-90-R)
Ambrogini et al. 130 Modest but significant beneficial effects on bodily pain, general health perception, vitality and mental health in individuals 1 year after parathyroidectomy compared with medical management No between-group differences 1 year after parathyroidectomy (SCL-90-R)
Bollerslev et al. 131 Modest but significant improvements in mental health and the mental component summary scores 1 year, but not two years, after parathyroidectomy compared with medical management (SF-36)
No between-group differences (Comprehensive Psychopathological Rating Scale)
PHPT, primary hyperparathyroidism; SCL-90-R, Symptom Checklist-90-Revised scale; SF-36, 36-Item Short-Form Health Survey.
Rolighed and colleagues 167 recently reported the results of a randomized, placebocontrolled study, which investi gated whether vitamin D supplementation improved QOL in PHPT. Subjects given 2,800 IU of cholecalciferol for 26 weeks before and 26 weeks following para hyroidectomy demonstrated significant improvements in 25hydroxyvitamin D levels. However, QOL and muscle strength were not improved with cholecalciferol alone, but QOL significantly improved following parathyroidectomy independent of the 25hydroxyvitamin D level. Aberg et al. 152 also showed that, although QOL improved fol lowing parathyroidectomy, no additive effect of vitamin D supplementation was evident at doses of 1,600 IU daily.
Outlook PHPT now often presents without overt target organ involvement. Asymptomatic PHPT becomes more evi dent as countries adopt biochemical screening methods. Revised guidelines have helped to identify who among these individuals are recommended to undergo parath yroidectomy. However, highresolution imaging of the skeleton and the kidneys have called attention to the fact that the absence of overt symptomatology does not rule out involvement. Patients with asymptomatic PHPT need renal and skeletal testing before clinical decisions can be made. With a more rigorous evaluative approach, it is likely that a greater proportion of patients will meet one or more guidelines for parathyroid surgery.
This Primer has highlighted several outstanding research issues that remain to be explored in PHPT. Our understanding of normocalcaemic PHPT with regard to diagnosis, natural history, epidemiology, pathophysio logy and target organ involvement all remain key ques tions to be addressed. The optimal steadystate value of 25hydroxyvitamin D and means by which vitamin D should be replaced in individuals with PHPT who are deficient in vitamin D need to be elucidated. A par ticularly vexing issue relates to neurocognitive features that often accompany patients with PHPT. Despite sev eral attempts to provide conclusive data on the puta tive associ ation between neurocognitive function and PHPT as well as possible changes after successful para thyroidectomy, we still lack clear evidence in support of this idea. Microstructural analyses of bone using non invasive highresolution imaging technology have given new insights into multiskeletal compartment involve ment in PHPT, involving both cortical and trabecu lar bone. More information is needed to determine how these findings relate to bone strength and fracture risk and the extent to which improvement might follow after successful parathyroid surgery. Although the latest guidelines 121 recommend a more vigorous approach to biochemical stone risk factor analysis in individuals with PHPT who have hypercalciuria, the predictive value and reversibility of stone risk after parathyroidectomy are not yet known.
